Tivozanib | KRN951 | VEGFR inhibitor | AmBeed-信号通路专用抑制剂

首页 / 抑制剂/激动剂 / / / Tivozanib

替沃扎尼 /Tivozanib 99%+

货号：A770204 同义名： KRN951;AV-951 产品仅供科研

Tivozanib is an inhibitor of VEGFR1, VEGFR2 and VEGFR3 with IC50s of 30 nM, 6.5 nM, 15 nM, respectively. It can also inhibit PDGFR and c-Kit.

Tivozanib 化学结构
CAS号：475108-18-0

Tivozanib 3D分子结构
CAS号：475108-18-0

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费分装

免费溶解
下载资料

Tivozanib 纯度/质量文件

货号：A770204 标准纯度：99%+ 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Mar. Drugs, 2024, 22(5): 194. Ambeed. [ A104599 ]; • Pharmaceuticals, 2024, 17(5): 570. Ambeed. [ A224421 ]; 更多 >

c-Kit 亚型比较
PDGFR 亚型比较
VEGFR 亚型比较

产品名称	c-Kit ↓ ↑	其他靶点	纯度
Tyrphostin AG1296	+ c-Kit (Swiss 3T3), IC50: 1.8 μM	PDGFR	99%+
Masitinib	+ Kit, IC50: 200 nM		99%+
Motesanib Diphosphate	+++ Kit, IC50: 8 nM		99%+
Ki8751	++ c-Kit, IC50: 40 nM		98+%
Tivozanib	++ c-Kit, IC50: 78 nM		99%+
Pazopanib	+ c-Kit, IC50: 140 nM		99%
Sitravatinib	+++ Kit, IC50: 6 nM		99%+
Pexidartinib	+++ Kit, IC50: 10 nM		99%+
Lactate	++++ c-Kit, IC50: 2 nM	FLT3	85%
Amuvatinib	+++ c-Kit (D816H), IC50: 10 nM		99%+
Imatinib Mesylate	+ c-Kit, IC50: 100 nM	PDGFR	99%
AZD2932	+++ c-Kit, IC50: 9 nM		98%
Axitinib	++++ Kit, IC50: 1.7 nM		98%
Dovitinib	++++ c-Kit, IC50: 2 nM	FLT3	99%+
Sunitinib	✔	FLT3	98%
OSI-930	+ Kit, IC50: 80 nM		99%+
Telatinib	++++ c-Kit, IC50: 1 nM		99%+
Dasatinib monohydrate	++ c-Kit (wt), IC50: 79 nM c-Kit (D816V), IC50: 37 nM	Src	98%
Dasatinib	++ c-Kit (wt), IC50: 79 nM c-Kit (D816V), IC50: 37 nM	Src	98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	PDGFR ↓ ↑	PDGFRα ↓ ↑	PDGFRβ ↓ ↑	其他靶点	纯度
Tyrphostin A9	+ PDGFR, IC50: 0.5 μM			EGFR	98%
Tyrphostin AG1296					99%+
Motesanib Diphosphate	++ PDGFR, IC50: 84 nM				99%+
Pazopanib	++ PDGFR, IC50: 84 nM				99%
Imatinib	+ PDGFR, IC50: 100 nM			c-Kit	98%
Imatinib Mesylate	+ PDGFR, IC50: 100 nM			c-Kit	99%
Sennoside B	✔				99%+
PP121	++++ PDGFR, IC50: 2 nM			mTOR,VEGFR	99%+
Crenolanib		++++ PDGFRα, Kd: 2.1 nM	++++ PDGFRβ, Kd: 3.2 nM		99%+
Masitinib		+ PDGFRα, IC50: 540 nM	+ PDGFRβ, IC50: 800 nM		99%+
Ki8751		++ PDGFRα, IC50: 67 nM		c-Kit	98+%
Tivozanib		++ PDGFRα, IC50: 40 nM	++ PDGFRβ, IC50: 49 nM		99%+
Ponatinib		++++ PDGFRα, IC50: 1.1 nM			98%
Amuvatinib		++ PDGFRα (V561D), IC50: 40 nM			99%+
Axitinib		+++ PDGFRα, IC50: 5.0 nM	++++ PDGFRβ, IC50: 1.6 nM		98%
CP-673451		+++ PDGFRα, IC50: 10 nM	++++ PDGFRβ, IC50: 1 nM		99%+
Telatinib		+++ PDGFRα, IC50: 15 nM		c-Kit	99%+
Nintedanib		++ PDGFRα, IC50: 59 nM	++ PDGFRβ, IC50: 65 nM		99+%
Avapritinib		++++ PDGFRα (D842V), IC50: 0.5 nM			99%+
MK-2461			+++ PDGFRβ, IC50: 22 nM		99%+
Lactate			+++ PDGFRβ, IC50: 27 nM	c-Kit,FLT3	85%
Linifanib			++ PDGFRβ, IC50: 66 nM		99%+
AZD2932			+++ PDGFRβ, IC50: 4 nM	c-Kit	98%
Dovitinib			+++ PDGFRβ, IC50: 27 nM	c-Kit,FLT3	99%+
Sorafenib			++ mPDGFRβ, IC50: 57 nM PDGFRβ, IC50: 57 nM		99%
Sunitinib			++++ PDGFRβ , IC50: 2 nM	FLT3	98%
Orantinib			+++ PDGFRβ, Ki: 8 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

产品名称	VEGFR1 ↓ ↑	VEGFR2 ↓ ↑	VEGFR3 ↓ ↑	其他靶点	纯度
Motesanib Diphosphate	++++ VEGFR1, IC50: 2 nM	++++ VEGFR2, IC50: 3 nM VEGFR2/Flk1, IC50: 3 nM	+++ VEGFR3, IC50: 6 nM	PDGFR,RET	99%+
Tivozanib	++ VEGFR1, IC50: 30 nM	+++ VEGFR2, IC50: 6.5 nM	++ VEGFR3, IC50: 15 nM		99%+
Brivanib	+ VEGFR1, IC50: 380 nM	++ Flk1, IC50: 25 nM VEGFR2, IC50: 25 nM			99%+
Regorafenib	+++ VEGFR1, IC50: 13 nM	+++ VEGFR2, IC50: 4.2 nM	+ VEGFR3, IC50: 46 nM	RET	98%
Pazopanib	+++ VEGFR1, IC50: 10 nM	++ VEGFR2, IC50: 30 nM	+ VEGFR3, IC50: 47 nM	PDGFR,c-Kit,FGFR	99%
Sitravatinib	+++ VEGFR1 (FLT1), IC50: 6 nM	+++ VEGFR2 (KDR), IC50: 5 nM	++++ VEGFR3 (FLT4), IC50: 2 nM		99%+
Foretinib	+++ VEGFR1/FLT1, IC50: 6.8 nM	++++ KDR, IC50: 0.86 nM	++++ VEGFR3/FLT4, IC50: 2.8 nM	Tie-2	99%+
MGCD-265 analog	++++ VEGFR1, IC50: 3 nM	++++ VEGFR2, IC50: 3 nM	++++ VEGFR3, IC50: 4 nM	Tie-2	99%+
Lactate	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	85%
AEE788	+ FLT1, IC50: 59 nM	+ KDR, IC50: 77 nM		EGFR	98+%
Linifanib	++++ VEGFR1/FLT1, IC50: 3 nM	++++ VEGFR2/KDR, IC50: 4 nM	+ VEGFR3/FLT4, IC50: 190 nM	FLT3	99%+
Vatalanib 2HCl	+ VEGFR1/FLT1, IC50: 77 nM	++ VEGFR2/KDR, IC50: 37 nM VEGFR2/Flk1, IC50: 270 nM	+ VEGFR3/FLT4, IC50: 660 nM	c-Kit,c-Fms	99%+
Axitinib	++++ VEGFR1/FLT1, IC50: 0.1 nM	++++ VEGFR2/KDR, IC50: 0.2 nM VEGFR2/Flk1, IC50: 0.18 nM			98%
Dovitinib	+++ VEGFR1/FLT1, IC50: 10 nM	+++ VEGFR2/Flk1, IC50: 13 nM	+++ VEGFR3/FLT4, IC50: 8 nM	c-Kit,FLT3	99%+
ZM 306416	+ VEGFR1, IC50: 0.33 μM			Src	99%+
KRN-633	+ VEGFR1, IC50: 170 nM	+ VEGFR2, IC50: 160 nM	+ VEGFR3, IC50: 125 nM	BTK,c-Kit	99%+
OSI-930	+++ FLT1, IC50: 8 nM	+++ KDR, IC50: 9 nM			99%+
Lenvatinib	++ VEGFR1/FLT1, IC50: 22 nM	++++ VEGFR2/KDR, IC50: 4.0 nM	+++ VEGFR3/FLT4, IC50: 5.2 nM		98%
NVP-BAW2881	+ hVEGFR1, IC50: 820 nM	+++ mVEGF2, IC50: 165 nM hVEGFR2, IC50: 9 nM	+ hVEGFR3, IC50: 420 nM		98%
Cediranib	+++ VEGFR1/FLT1, IC50: 5 nM	++++ VEGFR2/KDR, IC50: 0.5 nM		c-Kit	99%+
Nintedanib	++ VEGFR1, IC50: 34 nM	+++ VEGFR2, IC50: 13 nM	+++ VEGFR3, IC50: 13 nM	FLT3	99+%
BMS-794833		++ VEGFR2, IC50: 15 nM			99%+
SKLB1002		++ VEGFR2, IC50: 32 nM			98%
Cabozantinib S-malate		++++ VEGFR2/KDR, IC50: 0.035 nM			99+%
Ki8751		++++ VEGFR2, IC50: 0.9 nM		c-Kit	98+%
SU 5402		++ VEGFR2, IC50: 20 nM			98%
Rivoceranib Mesylate		++++ VEGFR2, IC50: 1 nM		RET	98+%
Ponatinib		++++ VEGFR2, IC50: 1.5 nM			98%
LY2874455		+++ VEGFR2, IC50: 7 nM			99%+
ZM323881 HCl		++++ VEGFR2, IC50: <2 nM			98%
AZD2932		+++ VEGFR-2, IC50: 8 nM		c-Kit	98%
Cabozantinib		++++ VEGFR2/KDR, IC50: 0.035 nM			98%
Sorafenib		++ VEGFR2, IC50: 90 nM VEGFR2/Flk1, IC50: 90 nM			99%
CYC-116		++ VEGFR2, Ki: 44 nM		FLT3	99%+
Golvatinib		++ VEGFR2, IC50: 16 nM			99%+
Sunitinib		+ VEGFR2 , IC50: 80 nM		FLT3	98%
RAF265		++ VEGFR2, EC50: 30 nM			99%+
PD173074					99%+
BFH772		++++ VEGFR2, IC50: 3 nM			99%+
Semaxinib		+ VEGFR2/Flk1, IC50: 1.23 μM			98%
Vandetanib		++ VEGFR2, IC50: 40 nM	+ VEGFR3, IC50: 110 nM	EGFR	98%
SAR131675			++ VEGFR3, IC50: 23 nM		99%+
ENMD-2076		+ VEGFR2/KDR, IC50: 58.2 nM	++ VEGFR3/FLT4, IC50: 15.9 nM	RET,FLT3	98%
Telatinib		+++ VEGFR2, IC50: 6 nM	++++ VEGFR3, IC50: 4 nM	c-Kit	99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Tivozanib 生物活性

靶点	c-Kit c-Kit, IC50:78 nM VEGFR1 VEGFR1, IC50:30 nM VEGFR1 VEGFR1, IC50:30 nM VEGFR3 VEGFR3, IC50:15 nM
描述	Tivozanib is a potent and selective VEGFR inhibitor for VEGFR1/2/3 with IC50 of 30 nM/6.5 nM/15 nM, and also inhibits PDGFR and c-Kit, low activity observed against FGFR-1, Flt3, c-Met, EGFR and IGF-1R.

Tivozanib 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
MCF7 cells		Proliferation assay		Antiproliferative activity against human MCF7 cells, IC50=0.38 μM	24583357

Tivozanib 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT03419572	-		Recruiting	January 5, 2021	-
NCT00970411	Solid Tumors	Phase 1	Completed	-	Japan ... 展开 >> Shizuoka, Japan 收起 <<
NCT01058655	Gastrointestinal Cancer	Phase 1 Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<

Tivozanib 参考文献

[1]Taguchi E, Nakamura K, et al. Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model. Cancer Sci. 2008 Mar;99(3):623-30.

[2]Nakamura K, Taguchi E, et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. Cancer Res. 2006 Sep 15;66(18):9134-42.

Tivozanib 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

2.20mL

0.44mL

0.22mL

10.99mL

2.20mL

1.10mL

21.98mL

4.40mL

2.20mL

Tivozanib 技术信息

CAS号	475108-18-0
分子式	C₂₂H₁₉ClN₄O₅
分子量	454.863

别名	KRN951;AV-951;KRN-951, Tivozanib
运输	蓝冰

存储条件

粉末 Keep in dark place,Inert atmosphere,Room temperature

液体 -20°C:3-6个月-80°C:12个月

溶解度

DMSO: 25 mg/mL(54.96 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

2% DMSO+30% PEG 300+water 1 mg/mL

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03419572	-		Recruiting	January 5, 2021	-
NCT00970411	Solid Tumors	Phase 1	Completed	-	Japan ... 展开 >> Shizuoka, Japan 收起 <<
NCT01058655	Gastrointestinal Cancer	Phase 1 Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02115 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 收起 <<
NCT01631097	Hepatic Impairment	Phase 1	Completed	-	United States, Florida ... 展开 >> Miami, Florida, United States Orlando, Florida, United States 收起 <<
NCT01058655	-		Completed	-	-
NCT01478594	Colorectal Cancer	Phase 2	Completed	-	-
NCT01030783	Advanced Renal Cell Carcinoma	Phase 3	Completed	-	-
NCT01076010	Advanced Renal Cell Carcinoma	Phase 3	Completed	-	-
NCT01835223	Advanced Adult Hepatocellular ... 展开 >>Carcinoma Non-Resectable Hepatocellular Carcinoma 收起 <<	Phase 1 Phase 2	Active, not recruiting	December 1, 2019	United States, New York ... 展开 >> Roswell Park Cancer Institute Buffalo, New York, United States, 14263 United States, Ohio Case Western Reserve University Cleveland, Ohio, United States, 44106 收起 <<
NCT01478594	-		Completed	-	-
NCT01745367	Triple Negative Breast Cancer	Phase 2	Terminated(low enrollment)	-	-
NCT00502307	Carcinoma, Renal Cell	Phase 2	Completed	-	India ... 展开 >> Vellore, Tamil Nadu, India, 632004 Kolkata, India Mumbai, India New Delhi, India Pune, India Russian Federation Astrakhan, Russian Federation Ioshkar-Ola, Russian Federation Kazan, Russian Federation Moscow, Russian Federation, 125284 Moscow, Russian Federation, 129128 Moscow, Russian Federation Novgorod, Russian Federation Obninsk, Russian Federation Pyatigorsk, Russian Federation Rostove-on-Don, Russian Federation Sochi, Russian Federation St. Petersburg, Russian Federation Tomsk, Russian Federation Ufa, Russian Federation Ukraine Cherkassy, Ukraine Dnepropetrovsk, Ukraine Donetsk, Ukraine Kharkov, Ukraine Lviv, Ukraine Uzhgorod, Ukraine Zaporizzhya, Ukraine 收起 <<
NCT01885949	Prostate Cancer	Phase 2	Active, not recruiting	June 2019	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 收起 <<
NCT01782313	Recurrent Adult Soft Tissue Sa... 展开 >>rcoma Stage III Adult Soft Tissue Sarcoma Stage IV Adult Soft Tissue Sarcoma 收起 <<	Phase 2	Completed	-	United States, Illinois ... 展开 >> Northwestern University Chicago, Illinois, United States, 60611 United States, Iowa University of Iowa Iowa City, Iowa, United States, 52246 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Missouri Washington University Saint Louis, Missouri, United States, 63110 United States, Wisconsin University of Wisconsin Madison, Wisconsin, United States, 53792 收起 <<
NCT01210846	Advanced Solid Tumors	Phase 1	Completed	-	United States, Arizona ... 展开 >> TGEN Clinical Research Service at Scottsdale Healthcare Scottsdale, Arizona, United States United States, Florida Florida Cancer Specialists Ft. Myers, Florida, United States United States, Indiana Horizon Oncology Research, Inc. Lafayette, Indiana, United States United States, Louisiana Jayne Gurtler MD, Laura Brinz MD, Angelo Russo MD and Janet Burroff MD APMC Metairie, Louisiana, United States United States, Maryland Associates in Oncology/Hematology Rockville, Maryland, United States United States, Oklahoma Oklahoma University Cancer Institute (OUCI) Oklahoma City, Oklahoma, United States United States, Tennessee Tennessee Onocology Nashville, Tennessee, United States United States, Washington Multicare Research Institute/Tacoma General Hospital Tacoma, Washington, United States 收起 <<
NCT01782313	-		Completed	-	-
NCT00660153	Colorectal Cancer ... 展开 >> Gastrointestinal Cancer 收起 <<	Phase 1	Completed	-	Netherlands ... 展开 >> University Medical Center Groningen; Internal Medicine, Department of Medical Oncology Groningen, Netherlands Erasmus Medical Center; Department of Medical Oncology Rotterdam, Netherlands 收起 <<
NCT01673386	Metastatic Renal Cell Carcinom... 展开 >>a 收起 <<	Phase 2	Completed	-	-
NCT02627963	Carcinoma, Renal Cell	Phase 3	Active, not recruiting	December 2019	-
NCT01728181	Non-small Cell Lung Cancer ... 展开 >> Stage IV Disease EGFR Unknown or Wild-type 收起 <<	Phase 1 Phase 2	Withdrawn(Stopped before appro... 展开 >>val due to ineffective drug) 收起 <<	March 2016	-
NCT01369433	Solid Tumors	Not Applicable	Completed	-	-
NCT00563147	Renal Cell Carcinoma	Phase 1	Completed	-	United States, California ... 展开 >> UCLA Jonsson Comprehensive Cancer Center Los Angeles, California, United States, 90095 Stanford University Stanford, California, United States, 94305 United States, Florida H. Lee Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Nebraska Nebraska Methodist Hospital Omaha, Nebraska, United States, 68114 United States, Texas The Methodist Hospital Research Institute Houston, Texas, United States, 77030 收起 <<
NCT01297244	Renal Cell Carcinoma	Phase 2	Completed	-	-
NCT00717340	Metastatic Breast Cancer	Phase 1	Completed	-	United States, Massachusetts ... 展开 >> Dana Farber Cancer Institute, Inc. Boston, Massachusetts, United States, 02115 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10021 Germany Universitaetsklinikum Essen Essen, Germany, D-45147 收起 <<
NCT00826878	Carcinoma, Non-Small-Cell Lung	Phase 1	Completed	-	United States, District of Col... 展开 >>umbia Georgetown University Washington, District of Columbia, United States, 20007 United States, Kansas Kansas University Medical Center Kansas City, Kansas, United States, 66160 United States, New York Memorial Sloan-Kettering New York, New York, United States, 10021 收起 <<
NCT01846871	Glioblastoma	Phase 2	Completed	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 收起 <<
NCT01306630	Advanced Solid Tumors ... 展开 >> Locally Advanced or Metastatic Breast or Colorectal Cancer 收起 <<	Phase 1	Completed	-	United States, Arizona ... 展开 >> Scottsdale, Arizona, United States, 85258 United States, Florida Fort Myers, Florida, United States, 33908 United States, Tennessee Nashville, Tennessee, United States, 37203 收起 <<
NCT01769885	Stage II Renal Cell Cancer ... 展开 >> Stage III Renal Cell Cancer 收起 <<	Not Applicable	Withdrawn	-	-
NCT01363778	Healthy	Phase 1	Completed	-	United States, Wisconsin ... 展开 >> Covance Clinical Research Unit, Inc. Madison, Wisconsin, United States, 53704 收起 <<
NCT01972516	Ovarian Cancer ... 展开 >> Fallopian Tube Cancer Primary Peritoneal Carcinoma 收起 <<	Phase 2	Terminated(due to slow accrual... 展开 >>) 收起 <<	-	United States, Massachusetts ... 展开 >> Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 收起 <<
NCT01972516	-		Terminated(due to slow accrual... 展开 >>) 收起 <<	-	-
NCT01853644	Recurrent Epithelial Ovarian C... 展开 >>ancer Recurrent Fallopian Tube Cancer Recurrent Primary Peritoneal Cancer 收起 <<	Phase 2	Active, not recruiting	October 2019	United States, Illinois ... 展开 >> Northwestern University Chicago, Illinois, United States, 60611 CDH-Delnor Health System - Northwestern Medicine Cancer Center Warrenville, Illinois, United States, 60555 收起 <<
NCT01363804	Healthy	Phase 1	Completed	-	United States, Florida ... 展开 >> Covance Clinical Research Unit, Inc. Daytona Beach, Florida, United States, 32117 收起 <<
NCT01834183	Renal Cell Carcinoma	Phase 2	Withdrawn(Sponsor Aveo has wit... 展开 >>hdrawn support for this trial.) 收起 <<	-	United States, Massachusetts ... 展开 >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Brigham and Women's Hospital Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 收起 <<
NCT01807156	-		Terminated(Primary endpoint no... 展开 >>t met) 收起 <<	-	-
NCT01316848	Food Effect of Tivozanib in He... 展开 >>alth Subjects 收起 <<	Phase 1	Completed	-	United States, Texas ... 展开 >> Covance Clinical Research Unit, Inc. Dallas, Texas, United States 收起 <<
NCT01807156	Hepatocellular Cancer	Phase 2	Terminated(Primary endpoint no... 展开 >>t met) 收起 <<	-	United States, Georgia ... 展开 >> Emory University, Winship Cancer Institute Atlanta, Georgia, United States, 30322 收起 <<
NCT03136627	Carcinoma, Renal Cell	Phase 1 Phase 2	Active, not recruiting	December 2018	France ... 展开 >> Bordeaux Hospital University Center (CHU) Bordeaux, France Center Léon Bérard Lyon, France Institut Paoli-Calmettes Marseille, France Centre Paul Strauss Strasbourg, France, 67065 Institut Gustave Roussy Villejuif, France, 94805 收起 <<

替沃扎尼 /Tivozanib 99%+

Tivozanib 纯度/质量文件

全球学术期刊中引用的产品

Tivozanib 生物活性

Tivozanib 细胞研究

Tivozanib 临床研究

Tivozanib 参考文献

Tivozanib 实验方案

Tivozanib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

c-Kit	c-Kit, IC50:78 nM
VEGFR1	VEGFR1, IC50:30 nM
VEGFR1	VEGFR1, IC50:30 nM
VEGFR3	VEGFR3, IC50:15 nM
VEGFR3	VEGFR3, IC50:15 nM
PDGFRα	PDGFRα, IC50:40 nM
PDGFRα	PDGFRα, IC50:40 nM
VEGFR2	VEGFR2, IC50:6.5 nM
VEGFR2	VEGFR2, IC50:6.5 nM
PDGFRβ	PDGFRβ, IC50:49 nM
PDGFRβ	PDGFRβ, IC50:49 nM

替沃扎尼 /Tivozanib 99%+

Tivozanib 纯度/质量文件

全球学术期刊中引用的产品

Tivozanib 生物活性

Tivozanib 细胞研究

Tivozanib 临床研究

Tivozanib 参考文献

Tivozanib 实验方案

Tivozanib 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z